We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Can-Fite

News List

Can-Fite BioPharma enrols first patient to study Covid-19 drug pharmaceutical-technology
March 09, 2021
Can-Fite BioPharma has enrolled the first patient in a Phase II study of its drug, Piclidenoson, to treat hospitalised patients with moderate to severe Covid-19.
Can-Fite announces pre-IND submission to US FDA for Piclidenoson in treatment of Covid-19 infected p pharmaceutical-business-review
May 21, 2020
Can-Fite BioPharma announced it has filed a pre-Investigational New Drug (IND) meeting request with the U.S. Food and Drug Administration (FDA) for its drug candidate Piclidenoson in the treatment of COVID-19 patients with moderate-to-severe symptoms.
Can-Fite says liver cancer trial is delayed—but it could be good news fiercebiotech
June 25, 2018
Israeli microcap Can-Fite BioPharma won’t get a readout from its midstage trial of liver cancer candidate namodenoson as soon as it hoped, but said the data so far are looking good.
Can-Fite 12 Months' Activities & Milestones for 2018 biospace
January 12, 2018
Can-Fite BioPharmaceuticals today announced its 2018 milestone, including activities involving rheumatoid arthritis / psoriasis drug Piclidenoson and liver disease drug Namodenoson.